Clinical trial
Open-label, Dose Ascending Safety, Tolerability, and Proof of Concept Study to Evaluate the Use of ANXV (Human Recombinant Annexin A5) in the Treatment of Subjects With Recently Diagnosed Retinal Vein Occlusion
NCT05532735 is registered in ClinicalTrials.gov with Annexin Pharmaceuticals AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-label, Dose Ascending Safety, Tolerability, and Proof of Concept Study to Evaluate the Use of ANXV (Human Recombinant Annexin A5) in the Treatment of Subjects With Recently Diagnosed Retinal Vein Occlusion
- Lead sponsor
- Annexin Pharmaceuticals AB
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 24, 2022
- Completion date
- November 11, 2024
- Enrollment
- 16 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.